Alzheimer disease: Identification of blood-based biomarkers
Nature Reviews Drug Discovery 17, 166 (2018).
doi:10.1038/nrd.2018.32
Author: Sarah Crunkhorn
There is a significant need for a minimally invasive, cost-effective and reliable method to diagnose early-stage Alzheimer disease. Building on previous work, Nakamura et al. demonstrate the use of immunoprecipitation coupled with mass spectrometry to measure plasma amyloid-β (Aβ) biomarkers. Using two independent data
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
More News: Alzheimer's | Drugs & Pharmacology